ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1600464
Reduced Abundance of Fusobacterium Signifies Cardiovascular Benefits of Sodium Glucose Cotransporter 2 Inhibitor in Type 2 Diabetes: A Single Arm Clinical Trial
Provisionally accepted
Shuhui Yang1*
Deng Jiankun1Xiaoxu Weng1Zhaojie Ma1Nie Lin1Yili Xiao1Rui Zuo2Yufei Hu2Canbin Zheng1Xiaoshan Zeng1Qimao Lin1
Kaijian Hou2*- 1Shantou Central Hospital, Shantou, Guangdong Province, China
- 2Shantou University, Shantou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The sodium glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been demonstrated cardiovascular benefits in patients with type 2 diabetes mellitus (T2DM). However, the underlying mechanism remains poorly understood.We conducted an 8-week, single-arm clinical trial, which enrolled 12 patients with inadequate glycemic control on metformin monotherapy. These patients were treated with SGLT2i dapagliflozin (10 mg/day). We assessed changes in clinical parameters pertinent to glucose metabolism and risk factors of cardiovascular disease (CVD), as well as alterations in the gut microbiota using macrogene sequencing.Results: Improvements were observed in anthropometric parameters, glucose metabolism, blood lipid-related indices, inflammatory markers, and endothelial cell function-related parameters. Concurrently, SGLT2i led to changes in composition and functional pathways of the gut microbiota, manifested as increased abundance of probiotics and decreased abundance of harmful bacteria. Importantly, reduced abundance of Fusobacterium was correlated with improvements in various clinical indicators.Conclusions: SGLT2i represents a superior initial therapeutic option for T2DM patients at risk of CVD. The cardiovascular benefits of SGLT2i may be attributed to shifts in the gut microbiota, particularly the reduced abundance of Fusobacterium.
Keywords: sodium glucose cotransporter 2 inhibitor, type 2 diabetes, cardiovascular disease, Gut Microbiota, Fusobacterium
Received: 26 Mar 2025; Accepted: 23 Apr 2025.
Copyright: © 2025 Yang, Jiankun, Weng, Ma, Lin, Xiao, Zuo, Hu, Zheng, Zeng, Lin and Hou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Shuhui Yang, Shantou Central Hospital, Shantou, Guangdong Province, China
Kaijian Hou, Shantou University, Shantou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.